60 Degrees Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

60 Degrees Pharmaceuticals hat ein Gesamteigenkapital von $6.0M und eine Gesamtverschuldung von $156.7K, was einen Verschuldungsgrad von 2.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $7.4M bzw. $1.5M.

Wichtige Informationen

2.6%

Verhältnis von Schulden zu Eigenkapital

US$156.67k

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$5.01m
Eigenkapital	US$5.96m
Gesamtverbindlichkeiten	US$1.46m
Gesamtvermögen	US$7.42m

Jüngste Berichte zur Finanzlage

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SXTPDie kurzfristigen Aktiva des Unternehmens ($6.9M) übersteigen seine kurzfristigen Passiva ($1.3M).

Langfristige Verbindlichkeiten: SXTPDie kurzfristigen Vermögenswerte des Unternehmens ($6.9M) übersteigen seine langfristigen Verbindlichkeiten ($147.9K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SXTP über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Verhältnis von Schulden zu Eigenkapital in den letzten 5 Jahren gesunken ist ( SXTP).

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: SXTP auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: SXTP hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 58.6% pro Jahr abnimmt

60 Degrees Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$4.68 loss

60 Degrees Pharmaceuticals, Inc. Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

New major risk - Share price stability

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment

60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center

60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

High number of new and inexperienced directors

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.4001 million.

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.400101 million.

60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine

60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc.'s Subsidiary 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Second quarter 2023 earnings released

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60 Degrees Pharmaceuticals, Inc. Registers ACLR8-LR

New major risk - Market cap size

High number of new and inexperienced directors

60 Degrees Pharmaceuticals Receives Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen